Formulary
Ondansetron: Uses, Dosing, Side Effects and Indian Brand Names
Ondansetron is a 5-HT3 receptor antagonist and the most commonly used antiemetic for chemotherapy-induced and post-operative nausea and vomiting. It has no dopaminergic side effects and is well tolerated, with QT prolongation being the main safety concern at higher doses.
MedNext Academy | 5 min read
Clinically reviewed by Awaiting clinical review
Ondansetron: Uses, Dosing, Side Effects and Indian Brand Names
Ondansetron is a 5-HT3 receptor antagonist and the most commonly used antiemetic for chemotherapy-induced and post-operative nausea and vomiting. It has no dopaminergic side effects and is well tolerated, with QT prolongation being the main safety concern at higher doses.
NEET PG High-Yield: Ondansetron is a 5-HT3 antagonist -- no EPS (unlike metoclopramide). Key differentiation: ondansetron for acute CINV, aprepitant (NK1 antagonist) for delayed CINV, dexamethasone for both. Ondansetron causes constipation (not diarrhoea). QT prolongation is the important safety concern. In the antiemetic hierarchy, cisplatin-level emetogenicity requires triple therapy.
Clinical overview
Ondansetron is the most widely used antiemetic in India and globally, and is considered the gold standard for chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), and radiation-induced emesis. It was introduced in the early 1990s and transformed the management of chemotherapy-related emesis, which was previously the most feared side effect of cancer treatment. Ondansetron is highly effective against acute CINV (first 24 hours) but less effective against delayed CINV (days 2-5), where NK1 receptor antagonists (aprepitant) are added. It has a favourable side-effect profile compared to older antiemetics like metoclopramide (which causes extrapyramidal side effects) and prochlorperazine. Ondansetron does NOT cause sedation, does NOT cause extrapyramidal reactions (no dopamine receptor blockade), and does NOT cause diarrhoea (in fact, it can cause constipation). In Indian clinical practice, ondansetron is used extensively for post-surgical nausea, hyperemesis gravidarum (off-label, with safety debate), gastroenteritis-related vomiting in children, and CINV prophylaxis. The main adverse effect of clinical concern is QT prolongation, particularly with IV doses exceeding 16 mg.
Pharmacological class
Ondansetron belongs to the Serotonin (5-HT3) receptor antagonist (antiemetic) class. Ondansetron selectively blocks serotonin 5-HT3 receptors both peripherally (on vagal afferent nerve terminals in the GI tract) and centrally (in the chemoreceptor trigger zone and the nucleus tractus solitarius). Chemotherapy and radiation cause release of serotonin from enterochromaffin cells in the gut mucosa, which activates 5-HT3 receptors on vagal afferents to trigger vomiting. By blocking these receptors, ondansetron prevents the emetic signal from reaching the vomiting centre.
Indian brand names and formulations
Available as: Emeset (Cipla), Ondem (Alkem Laboratories), Vomikind (Mankind Pharma), Zofer (Sun Pharma).
Tablets (4 mg, 8 mg), Oral dissolving tablets/films (4 mg, 8 mg), Injection (2 mg/mL in 2 mL and 4 mL ampoules), Oral solution/syrup (4 mg/5 mL)
Regulatory status
Ondansetron is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Schedule H prescription drug. NLEM 2022 listed. Maximum single IV dose should not exceed 16 mg (FDA warning for QT prolongation).
Indications
- Chemotherapy-induced nausea and vomiting (CINV -- acute phase)
- Post-operative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
- Hyperemesis gravidarum (off-label, debated safety)
- Acute gastroenteritis with vomiting in children (single dose to facilitate oral rehydration)
- Nausea and vomiting from other causes (hepatic failure, uraemia)
Dosing
CINV prophylaxis: 8 mg PO/IV 30 minutes before chemotherapy, then 8 mg every 12 hours for 1-2 days. PONV: 4 mg IV at induction of anaesthesia. Children (acute gastroenteritis): 0.15 mg/kg IV or 4 mg PO (single dose). Hyperemesis gravidarum: 4 mg PO/IV every 8 hours. Maximum single IV dose: 16 mg (not 32 mg -- FDA revised due to QT prolongation risk). No dose adjustment needed for renal impairment; reduce in severe hepatic impairment (max 8 mg/day).
Contraindications
- Known hypersensitivity to ondansetron or other 5-HT3 antagonists
- Concurrent use with apomorphine (profound hypotension and loss of consciousness)
- Congenital long QT syndrome
Adverse effects
- Headache (most common side effect)
- Constipation (5-HT3 blockade reduces GI motility)
- QT prolongation and risk of torsades de pointes (dose-dependent, especially IV >16 mg)
- Dizziness
- Transient elevation of liver transaminases
- Injection site reactions (IV use)
- Serotonin syndrome (rare, when combined with other serotonergic drugs)
Drug interactions
- Apomorphine -- contraindicated (profound hypotension)
- QT-prolonging drugs (haloperidol, amiodarone, quinolones) -- additive QT prolongation
- Serotonergic drugs (SSRIs, tramadol) -- theoretical risk of serotonin syndrome
- Tramadol -- ondansetron may reduce tramadol's analgesic effect (5-HT3 involvement in pain modulation)
- CYP3A4 inducers (rifampicin, phenytoin) -- reduce ondansetron levels
Pregnancy and lactation
Category B. Large population studies (>1.8 million pregnancies in Danish cohort) have not shown increased risk of major congenital malformations. However, some studies suggested a small increased risk of cardiac septal defects with first-trimester use, leading to ongoing debate. Ondansetron is widely used for hyperemesis gravidarum in India and globally when other antiemetics fail, though doxylamine + pyridoxine (vitamin B6) is the recommended first-line treatment.
Exam-style clinical scenario
A 45-year-old woman receiving cisplatin chemotherapy for ovarian cancer is prescribed antiemetic prophylaxis. She receives ondansetron 8 mg IV before chemotherapy but develops severe vomiting 48 hours later. What explains the delayed vomiting and how should it be managed? Answer: Cisplatin is a highly emetogenic chemotherapy agent that causes both acute CINV (first 24 hours, mediated by serotonin release) and delayed CINV (days 2-5, mediated by substance P/NK1 pathway). Ondansetron is effective for acute but not delayed CINV. Management of delayed CINV: add aprepitant (NK1 receptor antagonist) and dexamethasone. The recommended triple antiemetic regimen for highly emetogenic chemotherapy is: ondansetron + dexamethasone + aprepitant.
Cost in India
INR 20-50 per strip of 10 tablets (4 mg); IV injection: INR 15-30 per ampoule (4 mg/2 mL); oral dissolving film: INR 30-60
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why does ondansetron cause constipation while metoclopramide causes diarrhoea?
Serotonin (5-HT3) receptors in the enteric nervous system stimulate GI motility and secretion. Ondansetron blocks these receptors, reducing GI motility and causing constipation. Metoclopramide, in contrast, is a D2 antagonist and 5-HT4 agonist that enhances acetylcholine release in the myenteric plexus, increasing GI motility (prokinetic effect), which can cause diarrhoea.
Why is ondansetron contraindicated with apomorphine?
Apomorphine (a dopamine agonist used in Parkinson's disease) causes profound hypotension when combined with ondansetron through an unclear mechanism, possibly involving modulation of autonomic reflexes. Co-administration has caused loss of consciousness and cardiovascular collapse in reported cases. This is an absolute contraindication.
What is the triple antiemetic regimen for highly emetogenic chemotherapy?
For highly emetogenic chemotherapy (cisplatin, dacarbazine, cyclophosphamide >1500 mg/m2): (1) 5-HT3 antagonist (ondansetron) -- blocks acute serotonin-mediated emesis, (2) NK1 antagonist (aprepitant) -- blocks substance P-mediated delayed emesis, (3) Dexamethasone -- enhances efficacy of both agents through unclear mechanisms (possibly anti-inflammatory effects on the gut and CNS). This triple regimen reduces CINV from ~90% to <20%.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Ondansetron
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary